Medizone Home
×

Intas launches Razumab, the first biosimilar to Lucentis

Intas Pharmaceuticals has launched Razumab™, its biosimilar to Lucentis® (Ranibizumab).

Intas is the first company globally to develop and launch a biosimilar version of Ranibizumab. Razumab is manufactured under strict guidelines for sterile use in the eye and is offered as single dose vial, thus reducing the risk of contamination during use.

Ranibizumab is a therapeutic antibody fragment designed specifically for treating degenerative conditions of the eye. Ranibizumab is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), a common degenerative condition of the eyes in the elderly. It is also indicated for Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy in patients with Diabetic Macular Edema and vision loss resulting from choroidal neovascularization in pathologic myopia (mCNV).

“Intas’ Ranibizumab, Razumab™ is a 100% ‘Made In India‘ molecule, a feat achieved by the scientists at Intas and unparalleled till date. With the mission to provide global healthcare at affordable costs, Razumab will be about 25% cheaper than the imported Lucentis in the hand of the patient. Our objective is to make the treatment available to a wider patient pool, that is as yet denied treatment due to the high cost of imported Lucentis,” said Mr.Binish Chudgar, the Vice Chairman of the Company.

Razumab is the tenth biosimilar launched by Intas in India, by far the largest number of indigenously developed biosimilars by any company. Since 2004, when Intas launched its first biosimilar, Intas has constantly worked to bring the latest in biological therapies to Indian patients at affordable prices. With its robust pipeline of future products under development, Intas aims to continue on this endeavor.

Source: Intas Press release